You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
Post-hoc analysis of the SMA Independence Scale-Upper Limb Module (SMAIS-ULM) in individuals with Type 2 and non-ambulant Type 3 SMA using SUNFISH Part 2 data
Independence in activities of daily living is a key determinant of health-related quality of life in individuals with SMA. This poster investigated the impact of risdiplam▼on levels of independence in children, teenagers and adults with SMA, determined by changes in scores on the patient-reported (for patients aged ≥12–25 years) and caregiver-reported (for patients aged 2–25 years) SMAIS-ULM.
Request medical material
Would you like to receive this poster via email to view later?